Dose-volume metric-based prediction of radiotherapy-induced lymphocyte loss in patients with non-small-cell lung cancer treated with modern radiotherapy techniques.

Lymphopenia Non-small cell lung cancer Radiotherapy

Journal

Physics and imaging in radiation oncology
ISSN: 2405-6316
Titre abrégé: Phys Imaging Radiat Oncol
Pays: Netherlands
ID NLM: 101704276

Informations de publication

Date de publication:
Apr 2024
Historique:
received: 02 01 2024
revised: 12 05 2024
accepted: 25 05 2024
medline: 24 6 2024
pubmed: 24 6 2024
entrez: 24 6 2024
Statut: epublish

Résumé

Radiation-induced lymphopenia (RIL) is a common side effect of radiotherapy (RT) that may negatively impact survival. We aimed to identify RIL predictors in patients with non-small-cell lung cancer (NSCLC) treated intensity modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT). We retrospectively analysed data of 306 patients who underwent radical RT for NSCLC. Absolute lymphocyte count (ALC) loss was evaluated for each patient by fitting an exponential decay curve to data from first 45 days since treatment start, and percentage ALC loss relative to baseline was calculated based on area under the decay curve and baseline ALC. We compared IMRT and VMAT treatment plans and used linear regression to predict ALC loss. ALC decreased during RT in the whole patient group, while neutrophil counts remained stable and decreased only in those treated with concurrent chemoradiotherapy (CRT). Percentage ALC loss ranged between 11 and 78 % and was more strongly than lymphocyte nadir correlated with dose-volume metrics for relevant normal structures. We found evidence for the association of high radiation dose to the lungs, heart and body with percentage ALC loss, with lung volume exposed to 20-30 Gy being most important predictors in patients treated with IMRT. A multivariable model based on CRT use, baseline ALC and first principal component (PC1) of the dose-volume predictors showed good predictive performance (bias-corrected R Percentage lymphocyte loss is a robust measure of RIL that is predicted by baseline ALC, CRT use and dose-volume parameters to the lungs, heart and body.

Sections du résumé

Background and Purpose UNASSIGNED
Radiation-induced lymphopenia (RIL) is a common side effect of radiotherapy (RT) that may negatively impact survival. We aimed to identify RIL predictors in patients with non-small-cell lung cancer (NSCLC) treated intensity modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT).
Materials and Methods UNASSIGNED
We retrospectively analysed data of 306 patients who underwent radical RT for NSCLC. Absolute lymphocyte count (ALC) loss was evaluated for each patient by fitting an exponential decay curve to data from first 45 days since treatment start, and percentage ALC loss relative to baseline was calculated based on area under the decay curve and baseline ALC. We compared IMRT and VMAT treatment plans and used linear regression to predict ALC loss.
Results UNASSIGNED
ALC decreased during RT in the whole patient group, while neutrophil counts remained stable and decreased only in those treated with concurrent chemoradiotherapy (CRT). Percentage ALC loss ranged between 11 and 78 % and was more strongly than lymphocyte nadir correlated with dose-volume metrics for relevant normal structures. We found evidence for the association of high radiation dose to the lungs, heart and body with percentage ALC loss, with lung volume exposed to 20-30 Gy being most important predictors in patients treated with IMRT. A multivariable model based on CRT use, baseline ALC and first principal component (PC1) of the dose-volume predictors showed good predictive performance (bias-corrected R
Conclusion UNASSIGNED
Percentage lymphocyte loss is a robust measure of RIL that is predicted by baseline ALC, CRT use and dose-volume parameters to the lungs, heart and body.

Identifiants

pubmed: 38912008
doi: 10.1016/j.phro.2024.100593
pii: S2405-6316(24)00063-0
pmc: PMC11190719
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100593

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Zuzanna Nowicka (Z)

Department of Biostatistics and Translational Medicine, Medical University of Łódź, Łódź, Poland.

Kasper Kuna (K)

Department of Biostatistics and Translational Medicine, Medical University of Łódź, Łódź, Poland.

Mateusz Łaszczych (M)

Department of Biostatistics and Translational Medicine, Medical University of Łódź, Łódź, Poland.

Małgorzata Łazar-Poniatowska (M)

Department of Oncology and Radiotherapy, Medical University of Gdańsk, Faculty of Medicine, Gdańsk, Poland.

Bartosz Kamil Sobocki (BK)

Department of Oncology and Radiotherapy, Medical University of Gdańsk, Faculty of Medicine, Gdańsk, Poland.

Konrad Stawiski (K)

Department of Biostatistics and Translational Medicine, Medical University of Łódź, Łódź, Poland.

Michał Dąbrowski (M)

Department of Oncology and Radiotherapy, Medical University of Gdańsk, Faculty of Medicine, Gdańsk, Poland.

Konrad Bruski (K)

Department of Oncology and Radiotherapy, Medical University of Gdańsk, Faculty of Medicine, Gdańsk, Poland.

Adam Zięba (A)

Department of Radiotherapy, Medical University of Łódź, Łódź, Poland.

Mateusz Pajdziński (M)

Department of Radiotherapy, Medical University of Łódź, Łódź, Poland.

Emilia Staniewska (E)

3 Radiotherapy and Chemotherapy Department, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, Poland.

Marcin Miszczyk (M)

3 Radiotherapy and Chemotherapy Department, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, Poland.
Collegium Medicum, Faculty of Medicine, WSB University, Dąbrowa Górnicza, Poland.

Harald Paganetti (H)

Massachusetts General Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.

Wojciech Fendler (W)

Department of Biostatistics and Translational Medicine, Medical University of Łódź, Łódź, Poland.
Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Bartłomiej Tomasik (B)

Department of Oncology and Radiotherapy, Medical University of Gdańsk, Faculty of Medicine, Gdańsk, Poland.

Classifications MeSH